Altered ratios of pro‐ and anti‐angiogenic VEGF‐A variants and pericyte expression of DLL4 disrupt vascular maturation in infantile haemangioma
Open Access
- 9 March 2016
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 239 (2) , 139-151
Abstract
Infantile haemangioma (IH), the most common neoplasm in infants, is a slowly resolving vascular tumour. Vascular endothelial growth factor A (VEGF‐A), which consists of both the pro‐ and anti‐angiogenic variants, contributes to the pathogenesis of IH. However, the roles of different VEGF‐A variants in IH progression and its spontaneous involution is unknown. Using patient‐derived cells and surgical specimens, we showed that the relative level of VEGF‐A165b was increased in the involuting phase of IH and the relative change in VEGF‐A isoforms may be dependent on endothelial differentiation of IH stem cells. VEGFR signalling regulated IH cell functions and VEGF‐A165b inhibited cell proliferation and the angiogenic potential of IH endothelial cells in vitro and in vivo. The inhibition of angiogenesis by VEGF‐A165b was associated with the extent of VEGF receptor 2 (VEGFR2) activation and degradation and Delta‐like ligand 4 (DLL4) expression. These results indicate that VEGF‐A variants can be regulated by cell differentiation and are involved in IH progression. We also demonstrated that DLL4 expression was not exclusive to the endothelium in IH but was also present in pericytes, where the expression of VEGFR2 is absent, suggesting that pericyte‐derived DLL4 may prevent sprouting during involution, independently of VEGFR2. Angiogenesis in IH therefore appears to be controlled by DLL4 within the endothelium in a VEGF‐A isoform‐dependent manner, and in perivascular cells in a VEGF‐independent manner. The contribution of VEGF‐A isoforms to disease progression also indicates that IH may be associated with altered splicing. © 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.Keywords
Funding Information
- British Heart Foundation (FS/11/34/28860)
- Medical Research Council (MR/K013157/1)
- National Institutes of Health (HL096384)
This publication has 26 references indexed in Scilit:
- The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapyAngiogenesis, 2014
- Pericytes From Infantile Hemangioma Display Proangiogenic Properties and Dysregulated Angiopoietin-1Arteriosclerosis, Thrombosis, and Vascular Biology, 2013
- Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal outputBlood, 2011
- Recombinant Human VEGF165b Inhibits Experimental Choroidal NeovascularizationInvestigative Ophthalmology & Visual Science, 2010
- Inhibition of Delta-Like-4–Mediated Signaling Impairs Reparative Angiogenesis After IschemiaCirculation Research, 2010
- The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivoOncogene, 2010
- Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangiomaNature Medicine, 2008
- Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesisNature, 2007
- VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice VariantCancer Research, 2004
- Keratinocyte-Derived Vascular Permeability Factor (Vascular Endothelial Growth Factor) Is a Potent Mitogen for Dermal Microvascular Endothelial CellsJournal of Investigative Dermatology, 1995